CLAIMar 20

FDARxBench: Benchmarking Regulatory and Clinical Reasoning on FDA Generic Drug Assessment

UW
arXiv:2603.1953947.4h-index: 11
AI Analysis

This provides a domain-specific benchmark for regulatory and clinical reasoning, addressing needs in FDA generic drug assessment.

The authors tackled the problem of evaluating language models on document-grounded question-answering for FDA drug labels by introducing FDARxBench, a real-world benchmark, and found substantial gaps in factual grounding, long-context retrieval, and safe refusal behavior across models.

We introduce an expert curated, real-world benchmark for evaluating document-grounded question-answering (QA) motivated by generic drug assessment, using the U.S. Food and Drug Administration (FDA) drug label documents. Drug labels contain rich but heterogeneous clinical and regulatory information, making accurate question answering difficult for current language models. In collaboration with FDA regulatory assessors, we introduce FDARxBench, and construct a multi-stage pipeline for generating high-quality, expert curated, QA examples spanning factual, multi-hop, and refusal tasks, and design evaluation protocols to assess both open-book and closed-book reasoning. Experiments across proprietary and open-weight models reveal substantial gaps in factual grounding, long-context retrieval, and safe refusal behavior. While motivated by FDA generic drug assessment needs, this benchmark also provides a substantial foundation for challenging regulatory-grade evaluation of label comprehension. The benchmark is designed to support evaluation of LLM behavior on drug-label questions.

Foundations

The foundational work for this paper's niche, ranked by how specifically the neighbourhood builds on it — not by global fame.

Your Notes